Table 3.
Univariable Logistic Regression Analysis of the Factors Associated with Mortality
| Variables | Odds Ratio (95%CI) | P-value |
|---|---|---|
| Demographics | ||
| Age (years) | ||
| 30–50 | 0.58 (0.20–1.66) | 0.306 |
| > 50 | 2.48 (0 0.89–6.94) | 0.083 |
| Gender (male) | 0.77 (0.36–1.61) | 0.481 |
| Infection Site | ||
| Bacteremia | 1.22 (0.34–4.38) | 0.755 |
| Pulmonary infection | 2.37 (0.91–6.16) | 0.077 |
| Urinary infection | 1.23 (0.50–2.99) | 0.652 |
| Abdominal infection | 1.28 (0.29–5.59) | 0.739 |
| Comorbidities | ||
| Cerebral vascular disease | 0.81 (0.42–1.56) | 0.523 |
| Hypertension | 1.61 (0.80–3.24) | 0.179 |
| Diabetes | 1.63 (0.83–3.21) | 0.159 |
| Coma | 3.43 (1.62–7.23) | 0.001 |
| Solid malignancy | 5.60 (1.84–17.10) | 0.002 |
| Invasive Procedures | ||
| Mechanical ventilation | 2.82 (1.25–6.37) | 0.012 |
| Central venous catheter | 1.77 (0.87–3.58) | 0.115 |
| Foley catheter | 2.14 (0 0.82–5.59) | 0.122 |
| Nasogastric tube | 1.39 (0.64–3.06) | 0.404 |
| Clinical Characteristics | ||
| Leukopenia (<4×109/L) | 3.78 (0.87–16.48) | 0.076 |
| Anemia (<10 g/dL) | 1.36 (0.66–2.82) | 0.407 |
| Platelet count (<50×109/L) (<50×109/L) (<50×109/L) | 3.61 (1.21–10.76) | 0.021 |
| Aspartate aminotransferase (>60 IU/L) | 1.44 (0.39–5.34) | 0.584 |
| Total bilirubin (>35 μmol/L) | 1.24 (0.49–3.18) | 0.648 |
| Urea nitrogen (>7.5mmol/L) | 3.19 (1.59–6.38) | 0.001 |
| C-reactive Protein (CRP) | ||
| 10–50 mg/L | 0.38 (0.18–0.78) | 0.008 |
| >50 mg/L | 4.41 (2.13–9.16) | < 0.001 |
| Procalcitionin (PCT) | ||
| 0.5–2 ug/L | 0.53 (0.26–1.08) | 0.08 |
| >2 ug/L | 3.02 (1.53–5.95) | 0.001 |
| Duration of ICU (days) | ||
| <7 | 1.56 (0.47–5.17) | 0.465 |
| 7–30 | 1.18. (0.60–2.31) | 0.627 |
| >30 | 1.02 (0.48–2.19) | 0.953 |
| Antibiotic Treatment | ||
| Cefoperazone/sulbactam | 0.93 (0.42–2.04) | 0.86 |
| Piperacillin/tazobactam | 1.34 (0.67–2.68) | 0.41 |
| Carbapenems | 1.12 (0.18–2.21) | 0.057 |
| Quinolone | 1.08 (0.54–2.15) | 0.826 |
| Third generation cephalosporins | 0.71 (0.34–1.45) | 0.342 |
| Aminoglycoside | 1.82 (0.81–4.09) | 0.149 |
| Minocycline | 1.14 (0.47–2.77) | 0.767 |
| Tigecycline | 3.12 (1.46–6.69) | 0.053 |
| Colistin | 1.06 (0.09–11.93) | 0.964 |
| Tigecycline + carbapenems | 2.97 (0.64–13.76) | 0.165 |
| Colistin + carbapenems | 2.13 (0.13–34.79) | 0.594 |
| Carbapenems + aminoglycoside | 0.41 (0.05–3.61) | 0.423 |
| Proportion of XDR strains | 0.79 (0.38–1.64) | 0.526 |
| Continuous renal replacement therapy | 2.74 (0.79–9.39) | 0.111 |
| Sepsis | 5.13 (2.01–13.07) | 0.001 |
| Shock | 9.52 (4.48–20.20) | <0.001 |
| Polymicrobial infection | 1.18 (0.61–2.30) | 0.622 |
| gtr100+ | 5.47 (2.42–12.33) | <0.001 |